What is Ever/Body?
Ever/Body operates at the intersection of retail health and medical aesthetics, providing a curated suite of skincare services and products. By leveraging a tech-enabled service model, the company aims to demystify professional skincare, making high-quality dermatological treatments more accessible to a broader consumer base. Its market position is defined by a focus on clinical excellence combined with a modern, consumer-centric retail experience, effectively disrupting traditional dermatology practices through a scalable, brand-forward approach.
How much funding has Ever/Body raised?
Ever/Body has raised a total of $110.9M across 4 funding rounds:
Series A
$17M
Debt
$401K
Series B
$38M
Series C
$55.5M
Series A (2019): $17M with participation from Tiger Global Management, Redesign Health, ACME Capital, and Declaration Partners
Debt (2021): $401K led by PPP
Series B (2021): $38M supported by MetaProp, Declaration Partners, Redesign Health, Tiger Global Management, Acme Capital, Addition, Gaingels, and Fifth Wall
Series C (2022): $55.5M featuring Tiger Global Management, Declare Capital, and Acme Capital
Key Investors in Ever/Body
Tiger Global Management
Tiger Global Management is an investment firm deploying capital in both public and private markets. The company was founded in 2001 and is headquartered in New York City, New York.
Acme Capital
ACME is a San Francisco based early-stage venture capital firm investing in breakthrough enabling technologies and business model innovations disrupting massive sectors.
Declaration Partners
Declaration Partners LP is an investment company providing private equity, financial services, and investment management, founded in 2017 and based in New York.
What's next for Ever/Body?
Looking ahead, the infusion of capital from the latest round is expected to accelerate Ever/Body's expansion strategy. The company is likely to prioritize the opening of new locations, the integration of advanced diagnostic technologies, and the further development of its proprietary product lines. As the firm transitions from its scaling phase into a more mature enterprise-level operation, the focus will remain on maintaining service quality while optimizing unit economics. Investors will be monitoring the company's ability to maintain its competitive edge in the rapidly evolving medical spa landscape, particularly as it seeks to capture a larger share of the premium wellness market.
See full Ever/Body company page
